The global nonvenereal syphilis treatment market is estimated to garner a revenue of USD 440 Million by the end of 2035 by growing at a CAGR of ~9% in the projected years, i.e., 2023 – 2035. Further, the market generated a revenue of 220 Million in the year 2022. The growth of the market can be attributed to the improving coverage and accuracy of nonvenereal syphilis testing worldwide as well as the development of a novel rapid, point-of-care test (POCT) for confirmatory testing of active syphilis infection with the rising concern about the globally increasing transmission of bejel, especially among children living in tropical, subtropical, or warm arid climates, predominantly by direct contact. As per the World Health Organization data, more than 80,000 cases of bejel are reported every year worldwide.
Nonvenereal syphilis is an infectious disease common in some parts but rare in many parts of the world. The bejel infection is very similar to syphilis but its means of transmission typically comprises non-sexual skin contact or the common use of eating and drinking utensils against that of syphilis that is sexually transmitted. Concern about the spreading spiral bacteria of the genus Treponema has led to the increasing effort taken by governments as well as healthcare professionals worldwide to develop accurate diagnostic tools for the identification of infections caused by T. pallidum subspecies so that their treatments can be developed accordingly, which is expected to bring in revenue boost for the key market players in the nonvenereal syphilis treatment market.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~9% |
|
Base Year Market Size (2022) |
~ USD 280 Million |
|
Forecast Year Market Size (2035) |
~ USD 440 Million |
|
Regional Scope |
|
Growth Drivers
Challenges
The global nonvenereal syphilis treatment market is segmented and analyzed for demand and supply by treatment into antibiotics and topical treatment. Out of these segments, the antibiotics segment is estimated to gain the largest market share in the year 2035. The major factors applicable to the growth of the segment include the rapidly developing spectrum of antibiotics for the treatment of various bacterial pathogens-related infections worldwide. As per the Centers for Disease Control and Prevention (CDC), antibiotics such as Benzathine penicillin G can cure the early stages of syphilis with a single injection. CDC recommends 3 doses of long-acting Benzathine penicillin G at weekly intervals for latent syphilis of unknown duration. Moreover, Azithromycin as a single 2-g oral dose is found to be effective for treating primary and secondary syphilis among certain populations. Hence, the increasing need for the development of more such antibiotics along with the skyrocketing pharma research and development (R&D) research & development is expected to propel the antibiotics segment growth in the projected period. It was found that R&D spending in the pharmaceutical industry amounted to ~USD 238 billion globally in 2021.
The global nonvenereal syphilis treatment market is also segmented and analyzed for demand and supply by diagnosis into lesions testing, dark-field microscopy, and others. Amongst these segments, the lesion testing segment is expected to garner a significant share in the year 2035. The major factors applicable to the growth of the segment include the rising number of infection-related deaths worldwide as well as the increasing prevalence of genital ulcers disease (GUD) and the rising need to test nonvenereal genital lesions such as vitiligo, pearly penile papule, fixed drug eruptions, scabies, scrotal dermatitis, lichen planus besides other genital dermatoses such as sebaceous cyst, psoriasis, lichen sclerosus, plasma cell balanitis or Zoon's balanitis, granuloma annulare, lichen nitidus, lymphangioma circumscriptum, Paulo-necrotic tuberculid, squamous cell carcinoma, and tinea infections as they are spreading at a faster pace. It was found that infection-related deaths globally reached nearly 13·7 million deaths in 2019. All these factors are driving the rising investment in the development of accurate lesion testing, lesion biopsy, and skin biopsy techniques, expanding the scope of segment growth.
Our in-depth analysis of the global nonvenereal syphilis treatment market includes the following segments:
|
By Treatment |
|
|
By Diagnosis |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this Report
The Middle East and Africa nonvenereal syphilis treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed majorly to the existence of nonvenereal syphilis in regions of West Africa, the Mediterranean, and the Sahara owing to the lack of sanitization as well as the hot and humid climate. Moreover, the rising awareness of syphilis infections, along with its increasing prevalence is further expected to boost the market growth in this region. As per projections over 10 million people are infected with syphilis worldwide with the majority of these infected people found in sub-Saharan Africa and Asia. In African regions, especially in remote regions of Africa, the living conditions of the Africans in areas such as the Kimberley are considered to be conducive to the spread of Treponema species, hence it is expected that the market in this region will mark growth in the projected years.
The Asia Pacific nonvenereal syphilis treatment market, amongst the market in all the other regions, is projected to hold the second largest share in the projected years. The market growth in the projected years majorly includes the prospering travel and tourism, sex industry, migration of workers, and poor control measures as well as the rising emergence of syphilis, bejel, yaws, and pinta as a severe public health issue in underdeveloped & developing countries of Asia, South Asia, and the Western Pacific islands. The travel and tourism industry which contributed nearly USD 143 billion to the GDP in Southeast Asia in 2021, has its own pros and cons. Tourism not also attracts tourists but also results in the transmission of various pathogens from one country to another. Thus, the increasing awareness campaigns as well as the growing government spending on the development of proper diagnostic facilities together with rising investment in drug development to curb the spread of such diseases in middle and low-income countries is further expected to escalate the regional market growth.
Furthermore, the market in North America, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The growth of the market can be attributed majorly to the gradual spread of bejel on islands of the region such as in Cuba, as well as increasing government initiatives to curb the spread of Treponema pallidum subsp. endemicum (TEN) along with the development of rapid diagnostic tests (RDTs) that can better distinguish an active infection of syphilis, bejel, or yaws to facilitate early treatment to the patients is expected to boost the nonvenereal syphilis market in the region in the projected years.
Cipla Limited a multinational pharmaceutical company joint hands with Kemwell Biopharma Private Limited, a leading global CDMO, to make cost-effective biotherapeutics.
Sandoz, a subsidiary of Novartis, expanded its portfolio in manufacturing antibiotics with the acquisition of the Cephalosporin antibiotics business of GSK.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: The rising cases of bejel as well as the increasing augmentation of infectious diseases are the major growth factors driving the growth of the market.
Ans: The market is anticipated to attain a CAGR of ~9% over the forecast period, i.e., 2023 – 2035.
Ans: Challenges in the diagnostic landscape and testing models are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the Middle East and Africa region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Ans: The major players in the market are Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis International AG, Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by treatment, diagnosis, and by region.
Ans: The antibiotics segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?